Clinical Trial Update: CAR-T for R/R B-NHL [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update on CAR-T therapy targeting CD19/CD20/CD22/CD30 for relapsed or refractory non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• CAR-T CD19/CD20/CD22/CD30

Snippet

Sponsor: The First Affiliated Hospital of Soochow University | Conditions: Relapsed Non Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma | Phase 2 | Status: UNKNOWN